RBC Bioscience

RBC Bioscience Net Debt / EBITDA

The Net Debt to EBITDA of RBC Bioscience (6848.TWO) as of Oct 22, 2026 is 11.10. In the previous year, Net Debt to EBITDA was 27.96 — a change of -60.30% (lower).

Net Debt / EBITDA

11.10

YoY

-60.30%

Last updated:

Net Debt to EBITDA of RBC Bioscience is 2024 11.10 . Net Debt to EBITDA of RBC Bioscience was 2023 27.96 . It decreases by -60.30% lower compared to the previous year.

The RBC Bioscience Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
1.80 TWD
Jan 1, 2019
2.64 TWD
Jan 1, 2020
-0.34 TWD
Jan 1, 2021
7.91 TWD
Jan 1, 2022
52.27 TWD
Jan 1, 2023
27.96 TWD
Jan 1, 2024
11.10 TWD
The RBC Bioscience Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
11.10-60.30%
27.96-46.52%
52.27+560.82%
7.91-2,447.44%
-0.34-112.75%
2.64+46.90%
1.80—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Net Debt to EBITDA of RBC Bioscience is 11.10 in 2024.

Net Debt to EBITDA of RBC Bioscience changed from 27.96 to 11.10, representing a -60.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RBC Bioscience

All Key Metrics — RBC Bioscience